Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Income (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Operating Income for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Operating Income fell 3.09% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$957000.0 through Dec 2025, down 19.63% year-over-year, with the annual reading at -$957000.0 for FY2025, 19.63% down from the prior year.
  • Operating Income hit $2.4 million in Q4 2025 for Eton Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $7.4 million in Q4 2022 to a low of -$5.8 million in Q3 2021.
  • Historically, Operating Income has averaged -$316900.0 across 5 years, with a median of -$1.1 million in 2022.
  • Biggest five-year swings in Operating Income: skyrocketed 465.3% in 2022 and later crashed 367.78% in 2025.
  • Year by year, Operating Income stood at $1.3 million in 2021, then surged by 465.3% to $7.4 million in 2022, then plummeted by 126.83% to -$2.0 million in 2023, then skyrocketed by 221.73% to $2.4 million in 2024, then dropped by 3.09% to $2.4 million in 2025.
  • Business Quant data shows Operating Income for ETON at $2.4 million in Q4 2025, -$1.4 million in Q3 2025, and -$1.5 million in Q2 2025.